SCHEDULE: Pentwater Capital Discloses 7.5% Stake in Verve

Pentwater Capital Management LP and Matthew Halbower have disclosed a 7.5% beneficial ownership stake in Verve Therapeutics, Inc.

Summary

• Pentwater Capital Management LP and Matthew Halbower jointly reported beneficial ownership of 6,720,000 shares of Verve Therapeutics, Inc. Common Stock.
• This stake represents 7.5% of Verve Therapeutics, Inc.'s outstanding Common Stock.
• The percentage is calculated based on 89,143,237 shares outstanding as of May 7, 2025, as reported in Verve's Form 10-Q.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
• Pentwater Capital Management LP is a Delaware limited partnership and an investment adviser to certain funds (Pentwater Funds).
• Matthew Halbower is the sole shareholder of MCH PWCM Holdings Inc., the general partner of Pentwater Capital Management LP.

Sentiment

Score: 7

Explanation: The disclosure of a significant institutional stake by a reputable investment manager is generally viewed positively, as it indicates confidence and potential long-term interest in the company, without any negative information presented.

Positives

• A significant institutional investor, Pentwater Capital Management LP, has taken a 7.5% stake, indicating potential confidence in Verve Therapeutics, Inc.

Future Outlook

The filing does not contain forward-looking statements or guidance from Verve Therapeutics, Inc. It solely reports a beneficial ownership stake by an investment firm.

Industry Context

The disclosure of a significant stake by an investment management firm like Pentwater Capital Management in a biotechnology company such as Verve Therapeutics, Inc. can signal institutional interest in the gene editing or cardiovascular disease treatment sectors. While this filing does not provide specific industry trends, it highlights an investor's belief in the company's potential within its competitive landscape.

Stakeholder Impact

• Shareholders may view the acquisition of a significant stake by Pentwater Capital Management as a positive signal, potentially increasing investor confidence and demand for the stock.
• The company's management may see this as validation of their strategy and potential for increased institutional engagement.

Key Dates

Recommendation

This filing is a disclosure of a significant beneficial ownership stake by an institutional investor. While it signals institutional interest and can be a positive indicator, it does not provide new financial performance data, strategic updates, or operational insights that would warrant a 'buy' or 'sell' recommendation. It primarily confirms an existing investment position, suggesting a 'hold' as investors assess the implications of this institutional confidence in the context of the company's broader performance and market conditions.

Keywords

Verve Therapeutics, Pentwater Capital Management, Beneficial Ownership, Institutional Investment, Common Stock, Biotechnology, Gene Editing, Pharmaceuticals